aid: durata-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/durata-therapeutics.png
name: Durata Therapeutics
description: Durata Therapeutics was a clinical-stage pharmaceutical company founded in 2009 around anti-infective
  assets acquired from Pfizer's Vicuron division, headquartered first in Morristown, New Jersey and from 2012
  in Chicago, Illinois. Its lead candidate was dalbavancin, a long-acting semisynthetic lipoglycopeptide
  antibiotic taken into Phase III trials from 2011 for acute bacterial skin and skin-structure infections and
  later marketed as Dalvance. The company was backed by Canaan Partners and was acquired by Actavis (now
  Allergan) on November 17, 2014 for approximately $675 million, at which point it ceased to operate as an
  independent entity. Durata Therapeutics published no developer program, no public API, and no machine-readable
  API artifacts; its corporate domain duratatherapeutics.com no longer resolves. This profile is retained as a
  historical company record in the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/durata-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: defunct-no-api-surface
x-status: acquired
x-acquired-by: Actavis (now Allergan)
x-acquired-date: '2014-11-17'
x-defunct: true
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Health
- Anti-Infectives
- Drug Development
- Acquired
- Defunct
apis: []
common: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1
  notes: Company defunct since the 2014 Actavis acquisition; duratatherapeutics.com does not resolve (no NS/SOA).
    Domain-security, security-program, authentication and OAuth-scope probes all returned empty. No API,
    developer portal, SDK, or specification surface exists to harvest.